Connect with others who understand.

  •   Learn from expert-reviewed resources
  •   Real advice from people who’ve been there
  •   People who understand what you’re going through
Sign Up Log In
All Resources Treatments A-Z Personal Assistant What is This Site Help Center Crisis
Powered By

Top 4 search results for "Vitrakvi" in Resources. To see all results and access other features, sign up for free.

Posts
Resources
Q&A
People
Groups
Treatments
Biomarkers for Lung Cancer: 12 Things To Know
... gene fusions include:ALK Fusion Alectinib (Alecensa) Brigatinib (Alunbrig) Ceritinib (Zykadia) Crizotinib (Xalkori) Lorlatinib (Lorbrena) ROS1 Fusion: Ceritinib Crizotinib Lorlatinib Entrectinib (Rozlytrek) Repotrectinib (Augtyro) Taletrectinib (Ibtrozi) RET Fusion Pralsetinib (Gavreto) Selpercatinib (Retevmo) NTRK Fusion Entrectinib Larotrectinib (Vitrakvi ...
Biomarkers for Lung Cancer: 12 Things To Know
... gene fusions include:ALK Fusion Alectinib (Alecensa) Brigatinib (Alunbrig) Ceritinib (Zykadia) Crizotinib (Xalkori) Lorlatinib (Lorbrena) ROS1 Fusion: Ceritinib Crizotinib Lorlatinib Entrectinib (Rozlytrek) Repotrectinib (Augtyro) Taletrectinib (Ibtrozi) RET Fusion Pralsetinib (Gavreto) Selpercatinib (Retevmo) NTRK Fusion Entrectinib Larotrectinib (Vitrakvi ...
How Does Targeted Therapy for Lung Cancer Work?
... These drugs include entrectinib, larotrectinib (Vitrakvi), and repotrectinib.RETRET is another RTK that’s rarely mutated in NSCLC. Two targeted therapies, pralsetinib (Gavreto) and selpercatinib (Retevmo), have been developed to block the receptor from sending growth signals. ...
How Does Targeted Therapy for Lung Cancer Work?
... These drugs include entrectinib, larotrectinib (Vitrakvi), and repotrectinib.RETRET is another RTK that’s rarely mutated in NSCLC. Two targeted therapies, pralsetinib (Gavreto) and selpercatinib (Retevmo), have been developed to block the receptor from sending growth signals. ...
NSCLC Treatment Options: First-Line Treatments and Beyond
... selpercatinib (Retevmo) MET inhibitors, such as capmatinib (Tabrecta) and tepotinib (Tepmetko) HER2-directed drugs, such as ado-trastuzumab emtansine (Kadcyla), fam-trastuzumab deruxtecan-nxki (Enhertu), and zenocutuzumab-zbco (Bizengri) — which recently received accelerated approval TRK inhibitors, such as entrectinib (Rozlytrek) and larotrectinib (Vitrakvi ...
NSCLC Treatment Options: First-Line Treatments and Beyond
... selpercatinib (Retevmo) MET inhibitors, such as capmatinib (Tabrecta) and tepotinib (Tepmetko) HER2-directed drugs, such as ado-trastuzumab emtansine (Kadcyla), fam-trastuzumab deruxtecan-nxki (Enhertu), and zenocutuzumab-zbco (Bizengri) — which recently received accelerated approval TRK inhibitors, such as entrectinib (Rozlytrek) and larotrectinib (Vitrakvi ...
Lung Cancer Treatment Options
... These drugs work to inhibit the function of NTRK proteins for people whose lung cancer carries this gene mutation: Entrectinib Larotrectinib (Vitrakvi) Repotrectinib RET InhibitorsIn a handful of NSCLC cases, mutations in the RET gene produce a protein that causes cancer cells to grow. ...
Lung Cancer Treatment Options
... These drugs work to inhibit the function of NTRK proteins for people whose lung cancer carries this gene mutation: Entrectinib Larotrectinib (Vitrakvi) Repotrectinib RET InhibitorsIn a handful of NSCLC cases, mutations in the RET gene produce a protein that causes cancer cells to grow. ...